Amgen Polishes Enbrel Label
This article was originally published in The Pink Sheet Daily
Executive Summary
The TNF-inhibitor adds first-in-class claim for “major clinical response” in rheumatoid arthritis and gets approval for new once-weekly prefilled syringe. Five-year radiographic data also added to the label.